Malignant glioma
Conditions
Interventions
Initial therapy: Temozolomide (75mg/m2/day, administered orally everyday from day 1 to day 45) Vincristine (0.6mg/m2, Day2 and 3 div) IFN-beta (3 MIU/body/day, administered intravenously 3 days/
Sponsors
Department of Neurosurgery, Hirosaki University Graduate school of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. For patients who undergo surgery for first relapse disease; (i)histologically proven diagnosis of malignant glioma ; (ii)sufficient organ functions; (iii)written informed consent. 2. For patients who undergo surgery for recurrent disease; (i)histologically proven diagnosis of malignant glioma ; (ii)prior treatment for newly-diagnosed malignant glioma without postoperative radiotherapy; (iii)sufficient organ functions; (iv)written informed consent. 3. For patients who undergo surgery for recurrent disease; (i)histologically proven diagnosis of malignant glioma ; (ii)prior treatment for newly-diagnosed malignant glioma with postoperative radiotherapy; (iii)sufficient organ functions; (iv)written informed consent. 4. For patients who did not undergo surgery for first relapse disease; (i)clinically proven diagnosis of malignant glioma ; (ii)sufficient organ functions; (iii)written informed consent.
Exclusion criteria
Exclusion criteria: Patients who did not satisfy inclusion criteria.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| overall survival | — |
Secondary
| Measure | Time frame |
|---|---|
| progression-free survival, adverse events | — |
Countries
Japan
Contacts
Public ContactKenichiro Asano
Hirosaki University Graduate School of Medicine Department of Neurosurgery
Outcome results
None listed